Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2009

View Archived Issues

Mitsubishi Tanabe Pharma claims novel amine compounds for autoimmune diseases

New JAK inhibitors prepared and tested at Merck & Co.

Novel p38alpha MAPK inhibitors in development at Xcovery

Novel calcitonin gene-related peptide (CGRP) receptor antagonists disclosed by Merck & Co.

F2G claims novel antifungal agents

New cathepsin K inhibitors for treating osteoporosis imparted by AstraZeneca

EMEA grants Premacure orphan designation for Insmed's Iplex in infant ROP

Myriad acquires Panacos' HIV drug bevirimat

Neurologix initiates phase II clinical trial of gene transfer therapy for Parkinson's disease

Akesis discontinues sole clinical development program and files for bankruptcy

Phase III data support use of NGX-4010 in postherpetic neuralgia

Novartis launches Extavia for multiple sclerosis

Takeda initiates two phase III vedolizumab studies in inflammatory bowel disease

GSK's ofatumumab to be new clinical gold standard for CLL by 2012

Seattle and FDA reach agreement on SPA for trial of SGN-35 in Hodgkin lymphoma

BioDelivery and DNDi signed research and licensing agreement for Bioral Amphotericin B

Axikin, spin out of Actimis, reports funding for preclinical program

GlaxoSmithKline receives European approval to market orlistat 60 mg

ISTA reports positive phase IIb ecabet sodium trial results

Oncolys and Sysmex sign research agreement for circulating tumor cell diagnostic

The Leukemia & Lymphoma Society and Celator partner for CPX-351 in AML

Australian authorities approve Intercell's Japanese encephalitis vaccine

Gentium completes enrollment for the phase II/III European defibrotide trial

Stelara receives approval in Europe for moderate to severe plaque psoriasis

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...